Skip to main content
Ophthalmic gene therapy firm Quethera purchased by Astellas

Ophthalmic gene therapy company Quethera was purchased by Astellas Pharma in a deal that gives Quethera upfront and contingent payments of up to $110.3 million. Quethera's lead program is an undisclosed gene therapy in preclinical testing for patients with glaucoma.

Full Story: